Company Filing History:
Years Active: 1998-2003
Title: D Grant Gall: Innovator in Gastrointestinal Therapeutics
Introduction
D Grant Gall is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of gastrointestinal therapeutics, holding 2 patents that focus on the use of epidermal growth factor (EGF) in treating various gastrointestinal conditions.
Latest Patents
Gall's latest patents include a method of treating gastric ulcers through the administration of epidermal growth factor. This patent describes new utilities for EGF, particularly its effectiveness in preventing gastrointestinal colonization by pathogens. Another patent outlines the use of EGF as a gastrointestinal therapeutic agent, detailing methods for inhibiting or treating pathogen colonization in animals. Additionally, it describes how EGF can promote weight gain in animals when administered orally, such as through feed or drinking water. These innovations highlight EGF's potential in treating a wide range of intestinal infections, including enteric colibacillosis.
Career Highlights
D Grant Gall is associated with University Technologies International, Inc., where he continues to advance research in gastrointestinal health. His work has garnered attention for its practical applications in veterinary medicine and animal health.
Collaborations
Gall has collaborated with notable colleagues, including Andre Gerald Buret and James A Hardin, contributing to a dynamic research environment focused on innovative therapeutic solutions.
Conclusion
D Grant Gall's contributions to the field of gastrointestinal therapeutics through his patents on epidermal growth factor demonstrate his commitment to advancing medical science. His work not only addresses critical health issues but also opens new avenues for treatment in both human and veterinary medicine.